Review
doi: 10.1111/j.1600-0609.1987.tb00018.x.
Pharmacodynamic aspects of aclarubicin with special reference to daunorubicin and doxorubicin
- PMID: 3552720
- DOI: 10.1111/j.1600-0609.1987.tb00018.x
Item in Clipboard
Review
Pharmacodynamic aspects of aclarubicin with special reference to daunorubicin and doxorubicin
Eur J Haematol Suppl.
1987.
No abstract available
Similar articles
-
Interaction of aclarubicin with DNA as compared with daunorubicin and doxorubicin.Nihon Gan Chiryo Gakkai Shi. 1986 Dec 20;21(10):2343-55. Nihon Gan Chiryo Gakkai Shi. 1986. PMID: 3471823 No abstract available.
-
The anthracycline antineoplastic drugs.N Engl J Med. 1981 Jul 16;305(3):139-53. doi: 10.1056/NEJM198107163050305. N Engl J Med. 1981. PMID: 7017406 Review. No abstract available.
-
Activity of (7) anthracycline related compounds in an doxorubicin sensitive human small cell lung cancer line and its doxorubicin resistant descendant. Activity of doxorubicin, daunorubicin, 4-deoxyrubicin, 4-demethoxydaunorubicin, detorubicin, 4'-epidoxorubicin and mitoxantrone.Eur J Respir Dis Suppl. 1987;149:53-5. Eur J Respir Dis Suppl. 1987. PMID: 3034649 No abstract available.
-
Failure of aclacinomycin and 7-con-O-methylnogarol (7-OMEN) to decrease cardiac guanylate cyclase activity.Cancer Treat Rep. 1980 Oct-Nov;64(10-11):1127-8. Cancer Treat Rep. 1980. PMID: 6109566 No abstract available.
-
Clinical assessment of the structure-activity relationship of anthracyclines and related synthetic derivatives.Cancer Treat Rep. 1986 Jan;70(1):51-63. Cancer Treat Rep. 1986. PMID: 2935251 Review. No abstract available.
Cited by
-
Aclarubicin: contemporary insights into its mechanism of action, toxicity, pharmacokinetics, and clinical standing.Cancer Chemother Pharmacol. 2024 Aug;94(2):123-139. doi: 10.1007/s00280-024-04693-1. Epub 2024 Jul 4. Cancer Chemother Pharmacol. 2024. PMID: 38965080 Free PMC article. Review.
-
DNA damage independent inhibition of NF-κB transcription by anthracyclines.Elife. 2022 Dec 7;11:e77443. doi: 10.7554/eLife.77443. Elife. 2022. PMID: 36476511 Free PMC article.
-
In vitro evaluation of the potential of aclarubicin in the treatment of small cell carcinoma of the lung (SCCL).Br J Cancer. 1989 Dec;60(6):838-44. doi: 10.1038/bjc.1989.376. Br J Cancer. 1989. PMID: 2574988 Free PMC article.
-
Phase II study of high-dose aclarubicin in previously treated patients with small-cell lung cancer.Cancer Chemother Pharmacol. 1992;30(3):219-20. doi: 10.1007/BF00686316. Cancer Chemother Pharmacol. 1992. PMID: 1321008 Clinical Trial. No abstract available.
-
Postincubation with aclarubicin reverses topoisomerase II mediated DNA cleavage, strand breaks, and cytotoxicity induced by VP-16.Invest New Drugs. 1994;12(4):289-97. doi: 10.1007/BF00873043. Invest New Drugs. 1994. PMID: 7775129